Payment overview · 2025
General Payments
$295.92
9 reported records · 7 companies
Healthcare provider profile · identity verified
David Wayne Zimmerman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AIKEN, SC · NPI 1366649931
Verified facts
What the public records show
CMS Open Payments records show David Wayne Zimmerman, M.D. received $295.92 in general payments during 2025 across 9 reported records.
ABIOMED accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $90.30 | 30.5% | 1 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $55.32 | 18.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.83 | 16.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.42 | 13.3% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.73 | 7.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.66 | 7.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.66 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $295.92 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $55.32 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.42 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1514 | 414 |
| Amlodipine Besylate | Amlodipine Besylate | 903 | 252 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 749 | 206 |
| Lisinopril | Lisinopril | 657 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 645 | 160 |
| Hydrochlorothiazide | Hydrochlorothiazide | 489 | 141 |
| Metformin Hcl | Metformin Hcl | 448 | 124 |
| Losartan Potassium | Losartan Potassium | 381 | 109 |
| Allopurinol | Allopurinol | 288 | 76 |
| Sertraline Hcl | Sertraline Hcl | 277 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 271 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 89 |
| Ezetimibe | Ezetimibe | 248 | 78 |
| Omeprazole | Omeprazole | 220 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 63 |
| Potassium Chloride | Potassium Chloride | 199 | 60 |
| Simvastatin | Simvastatin | 175 | 48 |
| Gabapentin | Gabapentin | 158 | 49 |
| Alendronate Sodium | Alendronate Sodium | 152 | 46 |
| Eliquis | Apixaban | 148 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 34 |
| Trazodone Hcl | Trazodone Hcl | 143 | 47 |
| Montelukast Sodium | Montelukast Sodium | 139 | 41 |
| Glimepiride | Glimepiride | 134 | 43 |
| Ozempic | Semaglutide | 134 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 35 |
| Glipizide Er | Glipizide | 121 | 30 |
| Alprazolam | Alprazolam | 120 | 23 |
| Atenolol | Atenolol | 120 | 37 |
| Meloxicam | Meloxicam | 118 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 32 |
| Finasteride | Finasteride | 105 | 30 |
| Buspirone Hcl | Buspirone Hcl | 103 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 20 |
| Carvedilol | Carvedilol | 93 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 90 | 35 |
| Furosemide | Furosemide | 87 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 20 |
| Famotidine | Famotidine | 77 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 19 |
| Tramadol Hcl | Tramadol Hcl | 75 | 27 |
| Donepezil Hcl | Donepezil Hcl | 72 | 18 |
| Valsartan | Valsartan | 71 | 20 |
| Spironolactone | Spironolactone | 68 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 56 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Januvia | Sitagliptin Phosphate | 66 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 16 |
| Jardiance | Empagliflozin | 56 | 13 |
| Glipizide | Glipizide | 54 | 17 |
| Benazepril Hcl | Benazepril Hcl | 53 | 13 |
| Enalapril Maleate | Enalapril Maleate | 52 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | 17 |
| Azithromycin | Azithromycin | 51 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 16 |
| Prednisone | Prednisone | 50 | 40 |
| Celecoxib | Celecoxib | 48 | 16 |
| Nifedipine Er | Nifedipine | 48 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Diazepam | Diazepam | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 19 |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 27 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Mupirocin | Mupirocin | 39 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 33 |
| Estradiol | Estradiol | 34 | 12 |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 11 |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 29 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 12 |
| Tradjenta | Linagliptin | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Colchicine | Colchicine | 25 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 18 |
| Prolia | Denosumab | 25 | 14 |
| Sucralfate | Sucralfate | 25 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 20 |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Valacyclovir | Valacyclovir Hcl | 17 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Trulicity | Dulaglutide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Torsemide | Torsemide | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $295.92 · 9 records | ABIOMED | CLOTTRIEVER BOLD CATHETER, FREESTYLE LIBRE 3, INTELLIS ADAPTIVESTIM, JARDIANCE, QULIPTA, UBRELVY, VITALPATCH RTM, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error